title: Effects of lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproteins in heterozygotes for familial hypercholesterolemia.
abstract: We have studied the effect of lovastatin, an inhibitor of the rate-limiting enzyme in cholesterol biosynthesis (3-hydroxy-3-methylglutaryl coenzyme A reductase), alone and in combination with the bile acid sequestrant cholestyramine on lipid parameters in 30 heterozygous patients with familial hypercholesterolemia (FH) during a 20-week open trial. Lovastatin 40 mg bid (twice daily) decreased significantly total serum cholesterol, low density lipoprotein (LDL)-cholesterol, triglycerides and apolipoprotein B by 36%, 45%, 29% and 11%, respectively, while high density lipoprotein (HDL)-cholesterol and apolipoprotein A-I were increased significantly by 16% and 37%, respectively. These data are consistent with a reduction in both the number of LDL particles and in their cholesterol content. Addition of cholestyramine 4 g bid caused a significant further decrease in total serum cholesterol and LDL-cholesterol to a total of 43% and 61%, respectively. The addition of 4 g bid or 8 g bid of cholestyramine caused only minor changes in the other lipid parameters. No effect was found by these drugs on Lp(a) lipoprotein level. We conclude that lovastatin alone or in combination with a small dose of cholestyramine normalizes the lipid profile in most FH heterozygotes.
authors.affiliation: Medical Out-Patient Clinic, Ullevål Hospital, Oslo, Norway.
authors.forename: T P
authors.initials: TP
authors.lastname: Leren
authors.forename: I
authors.initials: I
authors.lastname: Hjermann
authors.forename: K
authors.initials: K
authors.lastname: Berg
authors.forename: P
authors.initials: P
authors.lastname: Leren
authors.forename: O P
authors.initials: OP
authors.lastname: Foss
authors.forename: L
authors.initials: L
authors.lastname: Viksmoen
mesh_terms: D000328:Adult; D001053:Apolipoproteins / Q000097:blood*; D002792:Cholestyramine Resin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D006579:Heterozygote; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D008055:Lipids / Q000097:blood*; D008148:Lovastatin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged
chemical_list: D001053:Apolipoproteins; D008055:Lipids; D002792:Cholestyramine Resin; D008148:Lovastatin